Side-by-side · Research reference
DSIPvsOvagen
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AHuman-MechanisticAUTO-DRAFTED8/36 cited
BTheoreticalHUMAN-REVIEWED2/42 cited
DSIP
Sleep modulator · Anti-stress
SQ · Pre-sleep · Daily during cycle
Ovagen
Khavinson Bioregulator · Ovarian
OvarianTarget tissue
Di/Tri-peptidePeptide length
AnimalEvidence tier
Oral / SQ · Protocol varies
01Mechanism of Action
Parameter
DSIP
Ovagen
Primary target
Multiple — modulates HPA axis + thalamic delta-wave generation (proposed)Schneider 1986
Ovarian tissue chromatin complexes
Pathway
Reduced cortisol/ACTH + enhanced delta-wave EEG activity → improved sleep onset + depthSchneider 1986
Tissue-specific peptide → Nuclear chromatin binding → Gene expression modulation → Cellular differentiation
Downstream effect
Faster sleep onset, increased delta sleep, reduced stress response, possible anxiolytic effectSchneider 1986
Proposed ovarian functional support, fertility regulation, hormonal homeostasis restoration
Feedback intact?
—
Presumed physiological — Khavinson peptides described as regulatory, not replacement
Origin
Endogenous peptide first isolated from rabbit blood during delta sleep; synthesised exogenouslySchneider 1986
Extracted from bovine/porcine ovarian tissue; short synthetic peptides (2–4 amino acids)
Antibody development
—
—
02Dosage Protocols
Parameter
DSIP
Ovagen
Standard dose
100–200 mcg SQ pre-sleepSchneider 1986
10–20 mg / day (oral) or 1–2 mg SQ
Extrapolated from Khavinson-school protocols; no ovagen-specific PubMed dose studies.
Frequency
Once daily, pre-sleep
Once daily or cyclical (10–20 days per month)
Cyclical protocols common in Khavinson bioregulator tradition.
Lower / starter dose
50 mcg pre-sleep
—
Duration
8–12 weeks per cycle
4–12 weeks per cycle
Khavinson protocols typically 1–3 months; repeat cycles as needed.
Reconstitution
Bacteriostatic water
—
Timing
30–60 min pre-sleep
—
Half-life
Short plasma; CNS effects last hours
—
Route
—
Oral (capsule) or subcutaneous
Oral absorption assumed for short peptides; SQ route mirrors other Khavinson bioregulators.
04Side Effects & Safety
Parameter
DSIP
Ovagen
Injection site reaction
Mild irritation
Possible mild erythema (SQ route)
Drowsiness
Expected effect (intentional)
—
Vivid dreams
Anecdotally reported
—
Long-term safety
Limited modern RCT data
Unknown — no PubMed-indexed RCTs
Pregnancy / OB
Avoid
—
Reported adverse events
—
None documented in indexed literature
Theoretical hormonal effects
—
Ovarian stimulation — monitor for estrogen-sensitive conditions
Absolute Contraindications
DSIP
- ·Pregnancy / breastfeeding
- ·Concurrent CNS-depressant therapy without supervision
Ovagen
- ·Active hormone-sensitive malignancy (breast, ovarian, endometrial)
- ·Pregnancy
Relative Contraindications
DSIP
- ·Severe sleep apnoea (untreated)
- ·Concurrent benzodiazepine / opioid use
Ovagen
- ·History of estrogen-sensitive tumors (monitor)
- ·Polycystic ovary syndrome (PCOS) — theoretical ovarian hyperstimulation risk
- ·Endometriosis or fibroids (estrogen-responsive conditions)
05Administration Protocol
Parameter
DSIP
Ovagen
1. Reconstitution
Add 1–2 mL bacteriostatic water to vial.
Typical dose: 10–20 mg once daily. Capsule form — taken on empty stomach, 20–30 min before meals. Khavinson tradition suggests morning administration.
2. Injection site
SQ — abdomen. Rotate sites.
1–2 mg per injection. Reconstitute lyophilised powder with sterile water if required. Inject into abdomen or thigh; rotate sites.
3. Timing
30–60 min pre-sleep.
Common pattern: 10–20 days on, 10 days off. Aligns with menstrual cycle phases in some protocols. Repeat cycles for 2–3 months, then assess.
4. Storage
Lyophilised: room temp. Reconstituted: refrigerate ≤30 days.
Lyophilised: room temperature, light-protected. Reconstituted: refrigerate 2–8 °C, use within 7–14 days.
5. Needle
29–31G insulin syringe.
—